CEO Dr Ross Macdonald joined ausbiz to discuss the development and the outlook for Cynata in 2022 following the receipt of a patent from Japan, the world’s second largest stem cell market.
Providing hope for people with diabetic foot ulcers (DFU), Cynata’s Phase I trial of CYP‑006TK has commenced and is now open for patient enrolment:
Investing in medical research projects with the potential to deliver better health outcomes to more Australians is a government priority with the Morrison government investing more than $25m through the Biomedical Translation Fund three, in cutting-edge companies including Cynata:
In big news, Cynata has inked a Manufacturing Services Agreement with Fujifilm Cellular Dynamics to manufacture and supply its Cymerus™ MSCs. Cynata CEO Dr Ross Macdonald sat down with Eddy Sunarto at Stockhead to discuss just how important this deal is for the Company
Leading up to Christmas and per expectations, Cynata announced its clinical trial of CYP‑006TK in patients with diabetic foot ulcers (DFU) had commenced and is now open for patient enrolment.